Addition of bromelain and acetylcysteine to gemcitabine potentiates tumor inhibition
Colon cancer
acetylcysteine
bromac®
bromelain
gemcitabine
in vivo
Journal
American journal of cancer research
ISSN: 2156-6976
Titre abrégé: Am J Cancer Res
Pays: United States
ID NLM: 101549944
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
11
2020
accepted:
08
02
2021
entrez:
7
6
2021
pubmed:
8
6
2021
medline:
8
6
2021
Statut:
epublish
Résumé
The combinations of Bromelain and Acetylcysteine (BromAc
Types de publication
Journal Article
Langues
eng
Pagination
2252-2263Informations de copyright
AJCR Copyright © 2021.
Déclaration de conflit d'intérêts
Professor D.L. Morris is the co-inventor and assignee of the intellectual property and co-owner and director of the sponsor company, Mucpharm Pty Ltd. Dr J. Akhter and Dr K. Pillai are co-inventors of the intellectual property. Dr A.H. Mekkawy, Dr K. Pillai, Dr J. Akhter, Mr K. Ke and Ms S.J. Valle are employed by Mucpharm Pty Ltd. The University of New South Wales (NSi) has assigned the IP through license 2017-0045 to Professor D.L. Morris (inventor).
Références
Glycobiology. 1999 Jan;9(1):13-9
pubmed: 9884402
Int J Cancer. 2014 Jan 15;134(2):478-86
pubmed: 23843173
J Biol Chem. 1960 Jan;235:99-107
pubmed: 14425299
Annu Rev Med. 2009;60:207-19
pubmed: 19630571
Oncogenesis. 2013 Jun 17;2:e51
pubmed: 23774063
Metallomics. 2018 Mar 1;10(3):414-425
pubmed: 29417972
Dis Colon Rectum. 2017 Oct;60(10):999-1017
pubmed: 28891842
Oncogene. 2013 Mar 28;32(13):1714-23
pubmed: 22580602
Anticancer Res. 2014 Feb;34(2):845-50
pubmed: 24511021
Oncology. 2006;70(2):106-14
pubmed: 16645323
Oncotarget. 2017 Feb 21;8(8):13059-13072
pubmed: 28055957
J Exp Clin Cancer Res. 2014 Nov 12;33:92
pubmed: 25425315
Free Radic Res. 2018 Jul;52(7):751-762
pubmed: 29742938
Int J Surg. 2016 Aug;32:65-70
pubmed: 27353848
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
Bioresour Technol. 2008 Jul;99(10):4386-93
pubmed: 17920262
Ann Oncol. 2010 May;21 Suppl 5:v70-7
pubmed: 20555107
Mol Cancer. 2017 Jul 6;16(1):116
pubmed: 28683746
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Oncotarget. 2015 Oct 20;6(32):33329-44
pubmed: 26436698
Anticancer Res. 2016 Jun;36(6):3224-5
pubmed: 27272863
Br J Cancer. 2009 Oct 6;101(7):1155-61
pubmed: 19738614
Clin Colon Rectal Surg. 2015 Dec;28(4):234-46
pubmed: 26648794
Integr Med (Encinitas). 2014 Feb;13(1):8-12
pubmed: 26770075
Am J Transl Res. 2020 Nov 15;12(11):7404-7419
pubmed: 33312377
Onco Targets Ther. 2013 Apr 16;6:403-9
pubmed: 23620673
Am J Cancer Res. 2016 Jan 15;6(2):350-69
pubmed: 27186409
Eur J Surg Oncol. 2021 Jan;47(1):115-122
pubmed: 31679953
Dose Response. 2009 Mar 24;7(3):208-20
pubmed: 19809540
Asian Pac J Cancer Prev. ;18(2):479-484
pubmed: 28345833
J Cancer. 2014 Jan 01;5(1):31-43
pubmed: 24396496
J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5
pubmed: 15467030
Eur J Pharmacol. 2014 Oct 5;740:364-78
pubmed: 25058905
Oncotarget. 2017 Nov 6;8(63):106888-106900
pubmed: 29290997
Anticancer Drugs. 2014 Feb;25(2):150-60
pubmed: 24366282
Mol Cancer. 2019 May 23;18(1):100
pubmed: 31122251
Biochim Biophys Acta. 2013 Aug;1830(8):4117-29
pubmed: 23618697